Medicare
The Centers for Medicare & Medicaid Services (CMS) July 13 issued its physician fee schedule proposed rule for calendar year (CY) 2024.
The Centers for Medicare & Medicaid Services today announced the Guiding an Improved Dementia Experience (GUIDE) Model, a voluntary national Medicare payment model beginning next July that aims to help dementia patients remain at home and improve quality of life for them and their caregivers
A series of recent developments in Congress are adding significant urgency to AHA’s fight against site-neutral payment and other policies that would irreparably damage hospitals’ abilities to care for their communities, including a move to use rate setting that would offer commercial insurers a…
Find out how the Value in Health Care Act of 2023 supports rural, underserved, primary care, and specialty practices in alternative payment models.
The American Hospital Association would like to provide feedback on sections of H.R. 4822, the “Health Care Price Transparency Act of 2023,” as well as H.R. 3284, the “Providers and Payers COMPETE Act.”
The Centers for Medicare & Medicaid Services (CMS) July 17 issued updated regulatory guidance regarding requirements for hospitals to assess patients and hospital environments for risks of patient harm. The guidance will influence how surveyors evaluate hospital compliance with Medicare…
Congress returns to Washington this week with a full legislative agenda before its scheduled August recess.
Congress is considering several pieces of legislation that would impose billions of dollars in additional Medicare payment cuts for services provided by hospital outpatient departments (HOPDs).
Proposals to reduce Medicare payment rates for hospital outpatient departments by aligning them with payment rates for independent physician offices and ambulatory surgery centers are based on the false assumption that Medicare overpays hospitals for outpatient services, when in fact hospitals…
Medicare will cover new Alzheimer’s drugs that receive traditional approval from the Food and Drug Administration when a beneficiary is diagnosed with mild cognitive impairment or Alzheimer’s disease dementia and has a physician participating in a registry with an appropriate clinical team and…